JP2023534528A5 - - Google Patents
Info
- Publication number
- JP2023534528A5 JP2023534528A5 JP2023503463A JP2023503463A JP2023534528A5 JP 2023534528 A5 JP2023534528 A5 JP 2023534528A5 JP 2023503463 A JP2023503463 A JP 2023503463A JP 2023503463 A JP2023503463 A JP 2023503463A JP 2023534528 A5 JP2023534528 A5 JP 2023534528A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- group
- cancer
- general formula
- meso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026033550A JP2026094330A (ja) | 2020-07-20 | 2026-03-03 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010696995.5 | 2020-07-20 | ||
| CN202010696995 | 2020-07-20 | ||
| CN202010783483.2 | 2020-08-06 | ||
| CN202010783483 | 2020-08-06 | ||
| CN202011223930 | 2020-11-05 | ||
| CN202011223930.5 | 2020-11-05 | ||
| CN202110410441.9 | 2021-04-16 | ||
| CN202110410441 | 2021-04-16 | ||
| PCT/CN2021/107297 WO2022017365A1 (zh) | 2020-07-20 | 2021-07-20 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033550A Division JP2026094330A (ja) | 2020-07-20 | 2026-03-03 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534528A JP2023534528A (ja) | 2023-08-09 |
| JP2023534528A5 true JP2023534528A5 (enExample) | 2024-07-11 |
| JP7863083B2 JP7863083B2 (ja) | 2026-05-20 |
Family
ID=79728998
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503463A Active JP7863083B2 (ja) | 2020-07-20 | 2021-07-20 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
| JP2026033550A Pending JP2026094330A (ja) | 2020-07-20 | 2026-03-03 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033550A Pending JP2026094330A (ja) | 2020-07-20 | 2026-03-03 | 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230257366A1 (enExample) |
| EP (1) | EP4183781A4 (enExample) |
| JP (2) | JP7863083B2 (enExample) |
| KR (1) | KR20230042057A (enExample) |
| CN (3) | CN120004860A (enExample) |
| AU (1) | AU2021314401A1 (enExample) |
| BR (1) | BR112023000817A2 (enExample) |
| CA (1) | CA3184711A1 (enExample) |
| MX (1) | MX2023000868A (enExample) |
| TW (1) | TWI923600B (enExample) |
| WO (1) | WO2022017365A1 (enExample) |
| ZA (1) | ZA202301992B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116462660A (zh) * | 2022-01-19 | 2023-07-21 | 江苏恒瑞医药股份有限公司 | 一种异喹啉酮类化合物的盐及其晶型 |
| MX2024008959A (es) * | 2022-01-19 | 2024-07-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Forma cristalina de derivado de isoindolina que contiene azufre. |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
| CA2681633C (en) * | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2017246452C1 (en) * | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| EP3381474A1 (en) * | 2017-03-27 | 2018-10-03 | Alfasigma S.p.A. | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| IL278854B2 (en) * | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| CA3121667A1 (en) | 2018-09-30 | 2020-04-02 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| EP3908582B1 (en) * | 2019-01-09 | 2025-11-12 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| AU2020348849A1 (en) * | 2019-09-19 | 2022-04-07 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
| ES2988714T3 (es) * | 2020-07-07 | 2024-11-21 | Celgene Corp | Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas |
-
2021
- 2021-07-20 CN CN202510102009.1A patent/CN120004860A/zh active Pending
- 2021-07-20 US US18/017,388 patent/US20230257366A1/en active Pending
- 2021-07-20 MX MX2023000868A patent/MX2023000868A/es unknown
- 2021-07-20 TW TW110126626A patent/TWI923600B/zh active
- 2021-07-20 AU AU2021314401A patent/AU2021314401A1/en active Pending
- 2021-07-20 CN CN202180041057.4A patent/CN115916768B/zh active Active
- 2021-07-20 JP JP2023503463A patent/JP7863083B2/ja active Active
- 2021-07-20 BR BR112023000817A patent/BR112023000817A2/pt unknown
- 2021-07-20 CN CN202510100913.9A patent/CN120004859A/zh active Pending
- 2021-07-20 CA CA3184711A patent/CA3184711A1/en active Pending
- 2021-07-20 EP EP21847148.0A patent/EP4183781A4/en active Pending
- 2021-07-20 WO PCT/CN2021/107297 patent/WO2022017365A1/zh not_active Ceased
- 2021-07-20 KR KR1020237005618A patent/KR20230042057A/ko active Pending
-
2023
- 2023-02-17 ZA ZA2023/01992A patent/ZA202301992B/en unknown
-
2026
- 2026-03-03 JP JP2026033550A patent/JP2026094330A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547952A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2022185110A5 (enExample) | ||
| JP2022185107A5 (enExample) | ||
| RU2018119173A (ru) | Производное бензофурана, способ его получения и его применение в медицине | |
| JP2023536948A (ja) | Ｅｇｆｒ阻害剤およびその製造方法と応用 | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2018516917A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| RU2019121527A (ru) | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения | |
| JP2019535744A5 (enExample) | ||
| IL291099B2 (en) | Aminothiazole compounds as c-kit inhibitors | |
| JP2008528467A5 (enExample) | ||
| JP2009511490A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2019517487A5 (enExample) | ||
| JP2015518899A5 (enExample) | ||
| JP2020503363A5 (enExample) | ||
| EP3291814A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP6380777B2 (ja) | ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物 | |
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| JP2015522650A5 (enExample) |